文献类型：期刊文献

英文题名：Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy

作者：Hou, Yong-Zhe[1,2,3];Zhang, Qin[2];Bai, Hai[1,2,4];Wu, Tao[1,2];Chen, Ya-Jie[2]

第一作者：Hou, Yong-Zhe

通信作者：Bai, H[1]

机构：[1]940th Hosp Joint Logist Support force Chinese Peop, Ctr Hematol Dis Chinese PLA, Dept Hematol, Lanzhou 730050, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Dept Clin Med Coll 1, Lanzhou 730030, Gansu, Peoples R China;[3]Key Lab Stem Cells & Gene Drugs Gansu Prov, Lanzhou 730050, Gansu, Peoples R China;[4]940th Hosp Joint Logist Support force Chinese Peop, Ctr Hematol Dis Chinese PLA, Dept Hematol, 333 Nanbinhe Rd, Lanzhou 730050, Gansu, Peoples R China

第一机构：940th Hosp Joint Logist Support force Chinese Peop, Ctr Hematol Dis Chinese PLA, Dept Hematol, Lanzhou 730050, Gansu, Peoples R China

通信机构：[1]corresponding author), 940th Hosp Joint Logist Support force Chinese Peop, Ctr Hematol Dis Chinese PLA, Dept Hematol, 333 Nanbinhe Rd, Lanzhou 730050, Gansu, Peoples R China.

年份：2023

卷号：11

期号：7

起止页码：1458

外文期刊名：WORLD JOURNAL OF CLINICAL CASES

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000952591800003)】；

基金：We sincerely thank the first clinical college of Gansu University of Chinese medicine for providing account number to allow us access to global database support. Supported by the 2022 Project of Innovation Foundation of Outstanding Graduate Students of Gansu Province; the Graduate Innovation Foundation of Major Project of Education Department of Gansu Province, No. lccx2021001; the Gansu Provincial Science and Technology Plan Project Assignment (Innovation Base and Talent Plan), No. 21JR7RA013; the Gansu Province Innovation Base and Talent Plan (Gansu Province Leukemia Clinical Research Center), No. 21JR7RA015; and the 2022 Hospital Project of The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, No. 2022yxky015.

语种：英文

外文关键词：Lymphoma; Programmed cell death 1 receptor; Immune checkpoint inhibitors; Immune-related adverse events; Nivolumab; Pembrolizumab

摘要：Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system surveillance. Recently, immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors (nivolumab and pembrolizumab) have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma patients. Accordingly, the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually, which results in an increasing number of patients developing immune-related adverse events (irAEs). The occurrence of irAEs inevitably affects the benefits provided by immunotherapy, particularly when PD-1 inhibitors are applied. However, the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further investigation. This review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors. A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma.